Vestech has been assisting Prostacare, the owners and developers of a novel treatment for Benign Prostatic Hypertrophy (BPH), in the development of their product including the IP strategy and working towards regulatory approval under CE Marking and with the FDA.

Working with the German vendors and the Singapore-based clinical researchers, Vestech has been tasked with bringing the device to fruition and achieving market entry.